Denintuzumab provides a CD19-targeting monoclonal antibody for lymphoma, leukemia, and antibody research. It recognizes CD19, a cell-surface protein expressed on B-lineage cells and many B-cell malignancies and specifically supports studies of antigen recognition, targeted cancer cell binding, and antibody-drug conjugate (ADC) development.
Key Features and Benefits
- CD19-Targeting Antibody: Recognizes CD19, a B-cell surface antigen widely studied in hematologic malignancies.
- Monoclonal Antibody Platform: Provides a targeted antibody specifically for investigating CD19 recognition and malignant B-cell targeting.
- CD19 Recognition: Supports investigation of CD19 expression, antibody binding, internalization, and antigen-specific cellular interactions.
- B-Cell Malignancy Targeting: Enables studies of antibody binding to CD19-expressing lymphoma and leukemia cells.
- ADC Development Platform: Provides the antibody component associated with Denintuzumab Mafodotin (SGN-CD19A), an investigational CD19-directed ADC containing an MMAF payload.
- Cellular Internalization Research: Supports investigation of antibody uptake and intracellular trafficking in CD19-expressing cells.
- Antibody Engineering Research: Useful specifically for studying antibody conjugation, antigen specificity, and targeted payload delivery strategies.
Applications
- Non-Hodgkin Lymphoma Research: Supports investigation of CD19-targeted antibody strategies in non-Hodgkin lymphoma models.
- Diffuse Large B-Cell Lymphoma Research: Useful for studying CD19 expression and antibody recognition in DLBCL models.
- Acute Lymphoblastic Leukemia Research: Supports evaluation of CD19-directed targeting strategies in B-cell acute lymphoblastic leukemia models.
- CD19-Positive Cancer Research: Enables investigation of antigen expression and antibody interactions in CD19-expressing malignant cells.
- B-Cell Biology Research: Supports studies of CD19 expression and its role in B-cell receptor-associated signaling.
- ADC Research: Provides a targeting antibody platform specifically for investigating CD19-directed payload conjugation and delivery.
- Antibody Binding Assays: Useful specifically for evaluating antigen recognition, binding specificity, and antibody-cell interactions.
- Cellular Internalization Studies: Supports investigation of antibody uptake and intracellular trafficking in CD19-expressing cells.
- Comparative Antibody Research: Especially useful for comparing CD19-targeting antibodies and antibody-mediated B-cell recognition strategies.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures for monoclonal antibody research materials. Maintain conditions that preserve antibody stability, structural integrity, and antigen-binding activity.
Denintuzumab provides a CD19-directed monoclonal antibody for investigating B-cell antigen recognition and targeted cancer cell binding and specifically supports lymphoma, leukemia, B-cell biology, antibody engineering, and ADC research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
